دورية أكاديمية
Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.
| العنوان: | Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups. |
|---|---|
| المؤلفون: | Amblard I; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France., Mercier F; Department of Surgical Oncology, University of Montreal, Montreal, Canada., Bartlett DL; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA., Ahrendt SA; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA., Lee KW; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA., Zeh HJ; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA., Levine EA; Department of Surgical Sciences-Oncology, Wake Forest Baptist Medical Center, Winston Salem, USA., Baratti D; Department of Surgery, Peritoneal Malignancy Program, National Cancer Institute, Milan, Italy., Deraco M; Department of Surgery, Peritoneal Malignancy Program, National Cancer Institute, Milan, Italy., Piso P; Department of Surgical Oncology, Barmherzige Brüder Krankenhaus Regensburg, Germany., Morris DL; Department of Surgery, University of New South Wales, Sidney, Australia., Rau B; Department of Surgical Oncology, Charite Campus Virchow Klinikum University of Berlin, Germany., Tentes AAK; Department of Surgery, Didimotichon General Hospital, Athens/Didimotichon, Greece., Tuech JJ; Department of Surgical Oncology, CHU Charles Nicolle, Rouen, France., Quenet F; Department of Surgical Oncology, Institut du Cancer de Montpellier, France., Akaishi E; Department of Surgical Oncology, Centro de Oncologia Hospital Sirio Libanes, Sao Paulo, Brazil., Pocard M; Department or Surgical Oncology, Hopital Lariboisière, Paris, France., Yonemura Y; Department of Surgical Oncology, Organization to Support Peritoneal Dissemination Treatment, Osaka, Japan., Lorimier G; Department of Surgical Oncology, ICO-Paul Papin, Angers, France., Delroeux D; Department of Surgical Oncology, CHU de Besançon, France., Villeneuve L; University of Lyon 1, EMR 37-38, France; Hospices Civils de Lyon, Unité de Recherche Clinique, Pôle Information Medicale Evaluation Recherche, Lyon, France., Glehen O; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France., Passot G; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France. Electronic address: guillaume.passot@chu-lyon.fr. |
| مؤلفون مشاركون: | PSOGI and BIG RENAPE working groups |
| المصدر: | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2018 Sep; Vol. 44 (9), pp. 1378-1383. Date of Electronic Publication: 2018 Jun 19. |
| نوع المنشور: | Comparative Study; Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8504356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2157 (Electronic) Linking ISSN: 07487983 NLM ISO Abbreviation: Eur J Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: London ; New York : Academic Press, [1985- |
| مواضيع طبية MeSH: | Registries*, Bile Duct Neoplasms/*therapy , Cytoreduction Surgical Procedures/*methods , Hyperthermia, Induced/*methods , Peritoneal Neoplasms/*therapy, Adult ; Aged ; Aged, 80 and over ; Bile Duct Neoplasms/mortality ; Bile Duct Neoplasms/secondary ; Female ; Follow-Up Studies ; France/epidemiology ; Humans ; Male ; Middle Aged ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Prognosis ; Prospective Studies ; Survival Rate/trends |
| مستخلص: | Background: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. Objective: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. Material and Methods: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. Results: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3-26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. Conclusion: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy. (Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.) |
| فهرسة مساهمة: | Investigator: J Abba, Department of Surgical Oncology, CHU Grenoble University, Grenoble, France.; K Abboud, Department of Surgical Oncology, CHU St Etienne, St Etienne, France.; M Alyami, Department of Surgical Oncology, Centre Hospitalier Lyon Sud - EMR 3738, Lyon 1 University, Lyon, France.; C Arvieux, Department of Surgical Oncology, CHU Grenoble University, Grenoble, France.; N Bakrin, Department of Surgical Oncology, Centre Hospitalier Lyon Sud - EMR 3738, Lyon 1 University, Lyon, France.; JM Bereder, Department of Surgical Oncology, CHU L'Archet 2, Nice, France.; D Bouzard, Department of Surgical Oncology, CHU Louis Mourier, Colombes, France.; C Brigand, Department of Surgical Oncology, CHRU Hautepierre, Strasbourg, France.; S Carrère, Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.; D Delroeux, Department of Surgical Oncology, CHU Jean Minjoz, Besançon, France.; F Dumont, Department of Surgical Oncology, ICO - René Gauducheau, St Herblain, France.; C Eveno, Department of Surgical Oncology, CHU Lariboisière, Paris, France.; O Facy, Department of Surgical Oncology, CHU Dijon, Dijon, France.; F Guyon, Department of Surgical Oncology, Institut Bergonié, Bordeaux, France.; R Kianmanesh, Department of Surgical Oncology, CHU Robert Debré, Reims, France.; R Lo Dico, Department of Surgical Oncology, CHU Lariboisière, Paris, France.; G Lorimier, Department of Surgical Oncology, CHU Angers, Angers, France.; F Marchal, Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.; P Mariani, Department of Surgical Oncology, Institut Curie, Paris, France.; P Meeus, Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.; S Msika, Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.; P Ortega-Deballon, Department of Surgical Oncology, CHU Robert Debré, Reims, France.; B Paquette, Department of Surgical Oncology, CHU Lariboisière, Paris, France.; P Peyrat, Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.; N Pirro, Department of Surgical Oncology, CHU La Timône, Marseille, France.; M Pocard, Department of Surgical Oncology, CHU Lariboisière, Paris, France.; J Porcheron, Department of Surgical Oncology, CHU St Etienne, St Etienne, France.; F Quenet, Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.; P Rat, Department of Surgical Oncology, CHU Dijon, Dijon, France.; O Sgarbura, Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.; E Thibaudeau, Department of Surgical Oncology, ICO - René Gauducheau, St Herblain, France.; JJ Tuech, Department of Surgical Oncology, CHU Charles Nicolle, Rouen, France.; F Zinzindohoue, Department of Surgical Oncology, Hôpital Européen Georges Pompidou, Paris, France.; SA Ahrendt, Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburgh, United States.; E Akaishi, Department of Surgical Oncology, Centro de Oncologia Hospital Sirio Libanes, Sao Paolo, Brazil.; SH Baik, Department of Surgery, Gangnam Severance Hospital - Yonsei University College of Medicine, Seoul, South Korea.; D Baratti, Department of Gastrointestinal Surgery, San Raffaele Scientific Institute, Milan, Italy.; A Bhatt, Department of Surgical Oncology, Fortis Hospitals Limited, Bangalore, India.; P Cachin, Department of Surgery, Akademiska sjukhuset, Uppsala University Hospital, Uppasala, Sweden.; W Ceelen, Department of Gastrointestinal Surgery, Gent University Hospital, Ghent, Belgium.; I De Hingh, Department of Surgery, Catharina Ziekenhuis, Eindhoven, Netherlands.; M De Simone, Department of Surgical Oncology, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.; P Dubé, Department of Surgery, University of Montreal, Montreal, Canada.; RP Edwards, Department of Surgery, First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.; J Franko, Department of Surgical Oncology, Mercy Medical Center, Baltimore, United States.; L Gonzalez-Bayon, Department of Surgical Oncology, Hospital Gregorio Marañón, Madrid, Spain.; V Gushchin, Department of Surgical Oncology, Mercy Medical Center, Baltimore, United States.; MP Holtzman, Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburgh, United States.; MC Hsieh, Department of General Surgery, Wan-Fang Hospital, Taipei, Taiwan.; D Kecmanovic, Department of Surgery, First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.; KW Lee, Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburgh, United States.; K Lehmann, Department of Surgery and Transplantation, University Hospital of Zurich, Zurich, Switzerland.; Y Liu, NPO to Support Peritoneal Surface Malignancy Treatment, Kyoto, Japan.; S Mehta, Division of Peritoneal Surface Oncology, Saifee Hospital, Mumbai, India.; DL Morris, Department of Surgery, University of New South Wales, Sydney, Australia.; S O'Dwyer, Department of Colorectal Surgery, Christie Cancer Center, Manchester, United Kingdom.; E Orsevigo, Department of Gastrointestinal Surgery, San Raffaele Scientific Institute, Milan, Italy.; PK Pande, Department of Surgical Oncology, BLK Superspeciality Hospital, New Delhi, India.; EJ Park, Department of Surgery, Gangnam Severance Hospital - Yonsei University College of Medicine, Seoul, South Korea.; JF Pingpank, Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburgh, United States.; P Piso, Department of Surgery, University of Regensburg, Regensburg, Germany.; F Rajan, Department of Surgical Oncology, Kovai Medical Centre, Coimbatore, India.; B Rau, Department of Surgical Oncology, Charite Campus Mitte University of Berlin, Berlin, Germany.; A Sardi, Department of Surgical Oncology, Mercy Medical Center Baltimore, United States.; L Sideris, Department of Surgery, University of Montreal, Montreal, Canada.; A Sommariva, Melanoma and Sarcoma Unit, Istituto Oncologico Veneto, Padua, Italy.; J Spiliotis, First Department of Surgical Oncology, Metaxa Cancer Memorial Hospital, Piraeus, Greece.; P Sugarbaker, Department of Surgical Oncology, Washington Hospital Center, United States.; AAK Tentes, Department of Surgery, Metropolitan Hospital, Athens, Greece.; M Teo, Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.; R Yarema, Department of Oncology and Medical Radiology Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.; R Younan, Department of Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.; SS Zaveri, Department of Surgical Oncology, Manipal Hospital, Bangalore, India.; HJ Zeh, Department of Surgery, University of Pittsburgh Medical Center, Shaydyside Hospital, Pittsburgh, United States. Keywords: Gallbladder; Hilar cholangiocarcinoma; Intra-hepatic cholangiocarcinoma; Klatskin |
| تواريخ الأحداث: | Date Created: 20180823 Date Completed: 20180905 Latest Revision: 20180905 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.ejso.2018.04.023 |
| PMID: | 30131104 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-2157 |
|---|---|
| DOI: | 10.1016/j.ejso.2018.04.023 |